SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03608878
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Randomized, Controlled, Open Label, Clinical Trial for Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in Hepatocellular Carcinoma Patients With GALNT14-rs9679162-non-TT Genotype
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
NCT03608878 Hepatocellular Carcinoma MeSH: Carcinoma Carcinoma, Hepatocellular
HPO: Carcinoma Hepatocellular carcinoma
2 Interventions
Name: adagloxad simolenin/OBI-821
Description: Adagloxad simolenin (OBI-822) is a glyco-conjugated protein comprised of a carbohydrate tumor antigen. Globo H allyl glycoside is covalently linked to a carrier protein KLH, presented in a dominant trimer form with molecular weight between 1200-1395 kDa., to form Adagloxad simolenin (OBI-822) (Globo H-KLH) OBI-821 is a saponin based adjuvant structurally similar to descriptions found in the literature for another adjuvant, QS-21. Adagloxad simolenin will be mixed with OBI-821 before administration.Type: Biologicaladagloxad simolenin arm
Name: TACE
Description: Transarterial chemoembolizationType: ProcedureTACE alone arm adagloxad simolenin arm
Primary Outcomes
Description: time-to-intrahepatic total tumor volume progression
Measure: time-to-ITTVP Time: From enrollment till 36 months of follow-up.Purpose: Treatment
Allocation: Randomized
Parallel Assignment
There is one SNP
SNPs
1 rs9679162
5. Child-Pugh functional class A or B. 6. GALNT14- rs9679162 "non TT" genotype 7.